Magnetic resonance spectroscopy (MRS) in the management of localized prostate cancer
Hailey D
Record ID 32003001149
English, French
Authors' objectives:
To summarize the available information on the use of magnetic resonance spectroscopy (MRS) in the management of localized prostate cancer.
Authors' recommendations:
The Canadian Cancer Society estimates that 18,800 Canadian men will be diagnosed with prostate cancer in 2003; 4,200 will die. The accuracy of MRS and MRI used in combination to stage localized prostate cancer is better than that of MRI alone, though the improvement seems to be modest. There is no information available on its effect on patient management or clinical outcomes. The use of superparamagnetic contrast material has been shown to increase the accuracy of MRI for lymph node metastases in prostate cancer. Improvements in the performance of MRI in imaging local prostatic disease might influence the potential usefulness of MRS as an additional test.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/
Year Published:
2003
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Costs and Cost Analysis
- Magnetic Resonance Spectroscopy
- Prostatic Neoplasms
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.